FINWIRES · TerminalLIVE
FINWIRES

訂正:ニュージャージー・リソーシズが第2四半期決算を発表、7~9%の成長目標を再確認

By

-- (見出しと第1~4段落を第2四半期決算を反映して修正し、数値を更新しました。) ニュージャージー・リソーシズ(NJR)は月曜日、第2四半期決算を発表し、2030年までの48億ドルから52億ドルの設備投資計画に基づき、7%から9%の増益を目指す第1四半期の複数年成長計画を再確認しました。 NJRは、ニュージャージー州の6つの郡で594,227件の顧客を抱え、事業規模を拡大していると述べています。 NJRは、約513メガワットの設備容量と約1.2ギガワットの開発パイプラインを持つ太陽光発電事業を推進しており、2026会計年度の年初来で既に約33メガワットの発電設備を稼働させていると付け加えました。 同社は、2026会計年度の設備投資計画を7億7,500万ドルから9億3,000万ドル、2027会計年度の設備投資計画を8億7,000万ドルから10億ドルと再確認しました。 NJRは、リーフ・リバー・プロジェクトなどを通じて貯蔵・輸送能力を拡大しており、これにより稼働ガス容量を約320億立方フィートから550億立方フィート以上に70%以上増加させることを目指していると発表した。 同社はまた、アデルフィア・ゲートウェイやステックマン・リッジなどのミッドストリームおよびインフラ資産を拡大するとともに、エネルギーサービス、太陽光発電の拡大、パイプライン投資によって支えられる長期的な需要増加をターゲットにしていると述べた。

Related Articles

Asia

Lottery Secures Agreement for 40-Year License Extension

Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.

$ASX:TLC
Asia

Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%

Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.

$ASX:GTK$NZE:GTK
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX